Table 5.
Association between RyR Active PCB concentration sum1 (dichotomized using a median split) and ASD and Non-TD
| ASD vs. TD | Non-TD vs. TD | ||||||
|---|---|---|---|---|---|---|---|
| Exposure | TD (n = 60) | ASD (n = 21) | Non-TD (n = 23) | OR (95% CI) | P-Value | OR (95% CI) | P-Value |
| Frequency (%) | |||||||
| RyR Active PCB Lipid-Standardized Crude Model | |||||||
| M1 (4.68 – 16.31 ng/g of lipid) | 33 (55) | 6 (29) | 13 (57) | Reference | Reference | ||
| M2 (16.74 – 170.03 ng/g of lipid) | 27 (45) | 15 (71) | 10 (43) | 3.06 (1.04 to 8.95) | 0.04 | 0.94 (0.36 to 2.48) | 0.90 |
| RyR Active PCB Lipid-Standardized Adjusted Model2,3 | |||||||
| M1 (4.68 – 16.31 ng/g of lipid) | 33 (56) | 6 (29) | 12 (57) | Reference | Reference | ||
| M2 (16.74 – 170.03 ng/g of lipid) | 26 (44) | 15 (71) | 9 (43) | 2.63 (0.87 to 7.97) | 0.09 | 0.77 (0.27 to 2.25) | 0.64 |
PCB = Polychlorinated Biphenyl, TD = Typical Development, ASD = Autism Spectrum Disorder, Non-TD = Non-Typical Development, RyR = Ryanodine receptor, M1 = Lowest 50% PCB concentration, M2 = Highest 50% PCB concentration
1
Sum included concentration from: PCB 52, PCB 84, PCB 95, PCB 136, and PCB 176 collected during the 3rd trimester of pregnancy
2
Loss of 3 observations due to missing prenatal vitamin use,
3
Adjusted for maternal education and prenatal vitamin use in month 1 of pregnancy